Access the full text.
Sign up today, get DeepDyve free for 14 days.
H. Holder, J. Blose (1992)
The reduction of health care costs associated with alcoholism treatment: a 14-year longitudinal study.Journal of studies on alcohol, 53 4
P. Sutton (1970)
Medical ManagementBritish Medical Journal, 2
M. Stern (1978)
Narcotic Antagonists: Naltrexone. Progress Report. NIDA Research Monograph 9American Journal of Psychiatry, 135
(1992)
16 WHO collaborating centre for international drug monitoring. Skin reactions and acamprosate. WHO ADR Newsletter 1999
L. Brahen, Thomas Capone, D. Capone (1988)
Naltrexone: Lack of Effect on Hepatic EnzymesThe Journal of Clinical Pharmacology, 28
R. Dupont, M. Gold (1995)
Withdrawal and Reward: Implications for Detoxification and Relapse PreventionPsychiatric Annals, 25
(2007)
Material p on of this article is prohibited
Philippe Witte (2004)
Imbalance between neuroexcitatory and neuroinhibitory amino acids causes craving for ethanol.Addictive behaviors, 29 7
K. Murthy (1997)
Psychosis during disulfiram therapy for alcoholism.Journal of the Indian Medical Association, 95 3
P. Chase, M. Biros (2002)
A retrospective review of the use and safety of droperidol in a large, high-risk, inner-city emergency department patient population.Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 9 12
M. Fortier-Beaulieu, C. Noblet, F. Cardot, E. Thomine, N. Moore, J. Hemet, J. Bourreille (1992)
Possible association of erythema multiforme with acamprosateThe Lancet, 339
G. Burnett, H. Reading (1970)
The pharmacology of disulfiram in the treatment of alcoholism.The British journal of addiction to alcohol and other drugs, 65 4
Campral (acamprosate calcium) delayed-release tablets
J. Chick, H. Howlett, M. Morgan, B. Ritson (2000)
United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol.Alcohol and alcoholism, 35 2
B. Mason, Fernando Salvato, L. Williams, E. Ritvo, R. Cutler (1999)
A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence.Archives of general psychiatry, 56 8
C. Gianoulakis (2004)
Endogenous opioids and addiction to alcohol and other drugs of abuse.Current topics in medicinal chemistry, 4 1
J. Chick (1999)
Safety Issues Concerning the Use of Disulfiram in Treating Alcohol DependenceDrug Safety, 20
(2007)
Institution (includes handling fees). (The Canadian GST tax of 7% will be added to the subscription price of all orders shipped to Canada
A. Thomson, C. Cook, R. Touquet, J. Henry (2002)
The Royal College of Physicians report on alcohol: guidelines for managing Wernicke's encephalopathy in the accident and Emergency Department.Alcohol and alcoholism, 37 6
S. O'Malley, A. Jaffe, G. Chang, R. Schottenfeld, R. Meyer, B. Rounsaville (1992)
Naltrexone and coping skills therapy for alcohol dependence. A controlled study.Archives of general psychiatry, 49 11
R. Anton, S. O'Malley, D. Ciraulo, R. Cisler, D. Couper, D. Donovan, D. Gastfriend, J. Hosking, B. Johnson, J. Locastro, R. Longabaugh, B. Mason, M. Mattson, W. Miller, H. Pettinati, C. Randall, R. Swift, R. Weiss, L. Williams, A. Zweben (2006)
Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.JAMA, 295 17
R. Saitz (2005)
Clinical practice. Unhealthy alcohol use.The New England journal of medicine, 352 6
M. Pirmohamed, C. Brown, L. Owens, C. Luke, I. Gilmore, A. Breckenridge, B. Park (2000)
The burden of alcohol misuse on an inner-city general hospital.QJM : monthly journal of the Association of Physicians, 93 5
B. Mason, E. Ritvo, R. Morgan, F. Salvato, G. Goldberg, B. Welch, E. Mantero-Atienza (1994)
A Double‐Blind, Placebo‐Controlled Pilot Study to Evaluate the Efficacy and Safety of Oral Nalmefene HCI for Alcohol DependenceAlcoholism: Clinical and Experimental Research, 18
D. Sax, C. Kornetsky, A. Kim (1994)
Lack of Hepatotoxicity with Naltrexone TreatmentThe Journal of Clinical Pharmacology, 34
M. Mayo-Smith (1997)
Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal.JAMA, 278 2
(2000)
Acamprosate : could adverse effects upset the treatment of alcohol dependence ?
B. Mason, E. Ritvo, R. Morgan, F. Salvato, G. Goldberg, B. Welch, E. Mantero-Atienza (1994)
A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence.Alcoholism, clinical and experimental research, 18 5
J. Garbutt, H. Kranzler, S. O'Malley, D. Gastfriend, H. Pettinati, B. Silverman, J. Loewy, Elliot Ehrich (2005)
Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial.JAMA, 293 13
C. Bouza, M. Angeles, A. Muñoz, J. Amate (2004)
Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review.Addiction, 99 7
R. Croop, Elizabeth Faulkner, D. Labriola (1997)
The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The Naltrexone Usage Study Group.Archives of general psychiatry, 54 12
M. Oscar, Cécile Bataillon, H. Bagheri, A. Quellec, F. Rolland, J. Montastruc (2003)
Acamprosate (Aotal®) : les effets indésirables peuvent-ils entraver le traitement du sevrage alcoolique ?Therapie, 58
L. Branchey, W. Davis, Kelvin Lee, R. Fuller (1987)
Psychiatric complications of disulfiram treatment.The American journal of psychiatry, 144 10
James Mitchell (1986)
NALTREXONE AND HEPATOTOXICITYThe Lancet, 327
K. Mann, P. Lehert, M. Morgan (2004)
The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis.Alcoholism, clinical and experimental research, 28 1
J. Sinclair (2001)
Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism.Alcohol and alcoholism, 36 1
J. Volpicelli, L. Volpicelli, C. O'brien (1995)
Medical management of alcohol dependence: clinical use and limitations of naltrexone treatment.Alcohol and alcoholism, 30 6
S. Karhuvaara, Kaarlo Simojoki, Antti Virta, M. Rosberg, E. Löyttyniemi, T. Nurminen, A. Kallio, R. Mäkelä (2007)
Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study.Alcoholism, clinical and experimental research, 31 7
N. Miller, M. Gold (1998)
Comorbid cigarette and alcohol addiction: epidemiology and treatment.Journal of addictive diseases, 17 1
M. Yen, H. Ko, F. Tang, R. Lu, Jau-Shyong Hong (2006)
Study of hepatotoxicity of naltrexone in the treatment of alcoholism.Alcohol, 38 2
N. Kobborg, P. Søgaard (1981)
DISULFIRAM HEPATITISInPharma, 146
Application to mail at periodicals mailing rates is pending at Rahway, NJ. POSTMASTER: send address changes to Adverse Drug Reaction Bulletin
(1992)
Sinus bradycardia, prolonged QT-interval, and ventricular defibrillation under haloperidol-and clonidine-therapy in alcohol withdrawal syndrome
C. O'brien (2005)
Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependenceCurrent Psychiatry Reports, 7
December 2007 No. 247 Founded in 1966 by Professor D M Davies, FRCP, FRCP Ed ISSN 0044–6394 Acute phase Adverse reactions to drugs used to Benzodiazepines treat alcoholism Benzodiazepines (primarily diazepam and chlordiazepoxide) have been Byron Theron & Saket Singhal shown to improve psychomotor agita- Department of Gastroenterology, Sandwell General Hospital, Lyndon, West Bromwich, UK tion associated with acute alcohol Correspondence to Byron Theron, MB, ChB, MRCP, Department of Gastroenterology, withdrawal safely and effectively. Sandwell General Hospital, Lyndon, West Bromwich, B71 4HJ, UK These drugs are generally considered well tolerated in a controlled environ- ment. The main concerns relate to Summary the risk of oversedation and respiratory The armamentarium of drugs used in the treatment of alcohol abuse has grown depression, particularly in patients with with newer and novel therapies introduced to improve compliance and adverse liver or lung disease and in the elderly. effect profiles. There is now a range of treatments particularly aimed at reducing These effects can be reversed by the use craving and improving abstinence rates, including opioid antagonists (both long- of flumazenil. acting and short-acting) and g-aminobutyric-acid receptor analogues, which The use of these drugs should ideally have a good evidence base and are
Adverse Drug Reaction Bulletin – Wolters Kluwer Health
Published: Dec 1, 2007
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.